Pathstone Family Office’s Ascendis Pharma A/S ASND Stock Holding History

Pathstone Family Office’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,242	Closed	-$262K	–	1211
2022 Q4	$262K	Sell	2,242 -22	-1%	-$2.55K	﹤0.01%	981
2022 Q3	$234K	Buy	+2,264	New	+$215K	﹤0.01%	1036
2021 Q1	–	Sell	-70	Closed	-$12K	–	705
2020 Q4	$12K	Hold	70	–	–	﹤0.01%	839
2020 Q3	$11K	Buy	+70	New	+$10.1K	﹤0.01%	584

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Pathstone Family Office's ASND Position: Q1 2023 in Review

Pathstone Family Office sold out of Ascendis Pharma A/S (ASND) in Q1 2023, closing a stake of 2,242 shares — an estimated $262K sold.

Pathstone Family Office first reported a position in ASND in Q3 2020 and held it in 4 quarters. The position peaked at $262K in Q4 2022. 163 funds tracked by Wall St. Rank hold ASND as of Q1 2023.

Pathstone Family Office reported no remaining Ascendis Pharma A/S position as of Q1 2023 after selling out during the quarter.
Pathstone Family Office sold 2,242 Ascendis Pharma A/S shares in Q1 2023, an estimated $262K.
Pathstone Family Office first reported a position in Ascendis Pharma A/S in Q3 2020 and held it in 4 quarters.
Pathstone Family Office's Ascendis Pharma A/S position peaked at $262K in Q4 2022.
163 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2023.

Based on Pathstone Family Office's 13F filing for Q1 2023, filed 15 May 2023.